Adult Vaccines Market Report 2026
Global Outlook – By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral Or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines), By Application (Influenza, DPT, Human Papillomavirus, Zoster, Pneumococcal, Hepatitis), By End Users (Healthcare Firms, Hospitals) – Market Size, Trends, Strategies, and Forecast to 2030
Adult Vaccines Market Overview
• Adult Vaccines market size has reached to $24.21 billion in 2025 • Expected to grow to $37.51 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Rising Healthcare Expenditure Drives Growth In Adult Vaccine Market • Market Trend: Adoption of mRNA Technology in Adult Vaccines to Enhance Immunization Coverage • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Adult Vaccines Market?
Adult vaccines refer to the vaccines that are used to induce an immune response against a disease causing pathogen in adults. These vaccines are used for preventing and treating diseases. Vaccines lessen the severity of illness in individuals who are more vulnerable, such as those with chronic health conditions or weakened immune systems. The main types of adult vaccines are monovalent and multivalent. A monovalent vaccine refers to a vaccine that contains the mRNA component of a single virus and generates an immune response for a single antigen. The technologies involved are live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. These are used in several applications, such as influenza, dPT, the human papillomavirus, zoster, pneumococcal disease, and hepatitis, and are used by healthcare firms and hospitals
What Is The Adult Vaccines Market Size and Share 2026?
The adult vaccines market size has grown strongly in recent years. It will grow from $24.21 billion in 2025 to $26.34 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, government immunization initiatives, development of novel vaccines, growing geriatric population, increasing healthcare infrastructure.What Is The Adult Vaccines Market Growth Forecast?
The adult vaccines market size is expected to see strong growth in the next few years. It will grow to $37.51 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advancement in mRNA and recombinant vaccine technologies, increasing investment in adult immunization programs, expansion of cold chain logistics, rising awareness of vaccine-preventable diseases, collaborations between pharma and biotech companies. Major trends in the forecast period include increasing adult vaccination awareness, expansion of immunization programs, development of combination vaccines, growth in chronic disease management vaccines, rising demand for travel and occupational vaccines.
Global Adult Vaccines Market Segmentation
1) By Vaccine Type: Monovalent, Multivalent 2) By Technology: Live Attenuated Vaccines, Inactivated Viral Or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines 3) By Application: Influenza, DPT, Human Papillomavirus, Zoster, Pneumococcal, Hepatitis 4) By End Users: Healthcare Firms, Hospitals Subsegments: 1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines 2) By Multivalent: Combination Vaccines, Multi-Antigen VaccinesWhat Is The Driver Of The Adult Vaccines Market?
The increased healthcare expenditure supported the growth of the adult vaccine market. Healthcare expenditure refers to the total cost of healthcare services provided to a population. Increased healthcare expenditure often leads to greater funding for medical research and development. By investing in vaccination programs and increasing access to vaccines, healthcare systems can reduce the burden of preventable diseases and improve overall population health. Additionally, adult vaccination can lead to significant cost savings by reducing healthcare utilization and the need for expensive treatments. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based health company, Canada's total health expenditure in 2023 is projected to reach $344 billion, which is an increase of over $9 billion compared to 2022. Therefore, the increased healthcare expenditure positively impacted the growth of the adult vaccine industry.Key Players In The Global Adult Vaccines Market
Major companies operating in the adult vaccines market are GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Adult Vaccines Market Trends and Insights
Major companies are operating in the adult vaccines market, focusing on developing technological advancements such as mRNA-based vaccines for rapid and precise immune response generation to meet the rising demand for adult immunization against respiratory diseases. An mRNA vaccine uses messenger RNA encapsulated in lipid nanoparticles to instruct human cells to produce specific viral proteins, eliciting an immune response without using live or attenuated virus. For instance, in May 2024, Moderna, a US-based biotechnology company, received FDA approval for mRESVI, an mRNA respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. The vaccine encodes the prefusion F glycoprotein of RSV and is delivered in single-dose, pre-filled syringes, enabling neutralizing antibody production, improving safety and efficacy compared to traditional inactivated or live-attenuated vaccines, and expanding adult immunization options.What Are Latest Mergers And Acquisitions In The Adult Vaccines Market?
In December 2023, AstraZeneca, a UK-based developer of respiratory and immune-therapeutic vaccines, acquired Icosavax for up to US$ 1.1 billion. Through this acquisition, AstraZeneca aims to expand its adult vaccine portfolio by integrating Icosavax’s virus-like particle (VLP) vaccine platform and advancing its lead candidate IVX A12, a combination RSV and hMPV vaccine targeting older adults. Icosavax, Inc. is a US-based biopharmaceutical company that develops virus-like particle (VLP) vaccines for respiratory infections in adults.
Regional Insights
North America was the largest region in the adult vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Adult Vaccines Market?
The adult vaccines market consists of sales of mRNA vaccines and viral vector vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Adult Vaccines Market Report 2026?
The adult vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adult vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Adult Vaccines Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $26.34 billion |
| Revenue Forecast In 2030 | $37.51 billion |
| Growth Rate | CAGR of 8.8% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Vaccine Type, Technology, Application, End Users |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |